NCT06379334Active, not recruiting
Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population
Identification of Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Patients
Source: ClinicalTrials.gov · Last updated 23 Apr 2024
Brief summary (registry, in English)
Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally. Early detection of hepatitis B virus-related HCC (HBV-HCC) in CHB with potential biomarkers has become a pressing and difficult challenge. Recent advancements in urinary proteomics offer a promising approach for HBV-HCC biomarker identification, utilizing Liquid chromatography with tandem mass spectrometry for urine proteome analysis. Differential analysis using limma in R software will uncover upregulated proteins in HBV-HCC.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 180 (estimated)
- First submitted
- 16 Apr 2024
- Start date
- Dec 2020
- Primary completion date
- Dec 2024
- Lead sponsor
- Peking Union Medical College Hospital
- NCT number
- NCT06379334
What you commit to
- Study type: Observational
- Planned participants: 180
- From Dec 2020 to the primary completion date, Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have taken drugs known to have definite hepatotoxicity within the past year;
Other illness
- Patients with chronic hepatitis C infection;
- Patients with autoimmune diseases;
- Patients with urinary system infections;
- Patients with acute infectious diseases;
- Patients with hepatitis B-related liver cancer who also have tumors other than primary hepatocellular carcinoma.
Other
- Patients with long-term heavy alcohol consumption;
- Patients with hematuria;
- Patients with significant proteinuria;
- Patients with tumors of the urinary system;
Who the study is looking for
- Age \> 18 years old;
- Previously healthy individuals without underlying diseases, confirmed to be free of hepatitis B infection through HBV serum markers, with regular physical examinations and blood biochemistry tests;
- Chronic hepatitis B patients diagnosed through HBV serum markers, alpha-fetoprotein (AFP) concentration, clinical features, or imaging examinations;
- Hepatitis B-related liver cancer patients with complete clinical data, preoperatively tested positive for HBsAg, diagnosed based on clinical features and imaging examinations preoperatively, and pathologically confirmed with HCC postoperatively;
- Patients with non-hepatocellular liver cancer, preoperatively diagnosed based on clinical features and imaging examinations, with negative HBsAg, and pathologically or by biopsy confirmed as non-hepatocellular liver cancer without liver metastasis, with complete clinical data and no liver metastasis;
- Able to independently sign an informed consent form.
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.